



25 MARCH

ONLINE |
PRESENCIAL

ATMPs: From Preclinical Discovery To First-in-Human Trials (ATMPs Series Biocat)

🕒 02:00 p.m.

📍 VHIR Edifici Central meeting room | Floor 0

Program

14.00h –14:15h **Registration**

14.10h- 14.15h Welcome and Introduction (Dr. Jasmina Zanoncello – VHIR & Dr. Miguel Salas – BIOCAT)

14:15h –14:50h **Talk- 'Welcome and Vall d'Hebron University Campus as leaders in clinical research'**

Dr. Xavier Cañas (Director of Commercial and Contracted Clinical Research at Vall d'Hebron Institut of Research)

14:50h – 15:10h **Talk-'Kymriah and the CAR-T Revolution: Lessons from the First FDA Approval and the Road Ahead'**

Dr. Nuria Diez (Clinical Research Medical Advisor at Novartis)

15:10h - 15:30h **Talk-'From Bench to Trial: Regulatory Requirements for ATMP Development'**

Dr. Silvia Martin Lluesma (Head of Advanced Therapies Program at VHIO)

15:30h – 16:05h **Round Table 'From Preclinical to First-in-Human – Ethical, Regulatory, and Trial Design Challenges in ATMP development'**

Moderator: Dr. Miguel Chillón (ICREA researcher, Director of the UAB-VHIR Joint Unit and Coordinator of the CORE of Innovative and Advanced Therapies VHIR)

Panelists: Dr. Maria Castellà (ATMP Development, CMC, RA-Asphalion), Dr. Esteve Trias (Expert in ATMP Development, Regulatory and Manufacturing), Dr. Núria Gavalda (Strategy & Innovation Director Advanced Therapies Platform Director, BST)

16:05 – 16:20h **Coffee Break**

16:20h – 16:40h **Talk 'Developing Academic Therapies: An Academic Development Model'**

Dr. Hugo Calderón (Research at Immunogenetics and immunotherapy in autoinflammatory and immune responses group, Hospital Clínic)

16:40h – 17:15h **Round Table:'Managing Uncertainty in ATMPs: High-Risk Administration, Uncertain Long-Term Durability, Immunogenicity, and Patient-Specific Biological Barriers'**

Moderator: Miquel Salas (Senior Innovation Project Manager – Advanced Therapies Network of Catalonia)

Panelists: Dr. Josefina Cortés (Responsible of the Lupus Research Unit at VHIR), Dr. Alena Gros (Cancer Immunology and Immunotherapy Group Leader at VHIO), Dr. Miguel Mulet, (CEO de Terafront), Dr. Hugo Calderón (Research at Immunogenetics and immunotherapy in autoinflammatory and immune responses group, Hospital Clínic)